Please login to the form below

Not currently logged in
Email:
Password:

PD-L1 inhibitors

This page shows the latest PD-L1 inhibitors news and features for those working in and with pharma, biotech and healthcare.

AbbVie cures STING fever with Mavupharma acquisition

AbbVie cures STING fever with Mavupharma acquisition

checkpoint inhibitors like the PD-1/PD-L1 antagonists which remove a brake on immune responses to malignant cells.

Latest news

  • Keytruda monotherapy fails in triple negative breast cancer Keytruda monotherapy fails in triple negative breast cancer

    The disease, which accounts for 10-20% of all breast cancers, is seen as a key area of expansion for the PD-1 and PD-L1 checkpoint inhibitors, and Roche’s ... That approval was a first for checkpoint inhibitors in TNBC, but differed in that it was a

  • Merck claims key FDA okay for Bavencio in kidney cancer Merck claims key FDA okay for Bavencio in kidney cancer

    Will help boost underwhelming revenues. For the new generation of PD-1/PD-L1 inhibitors for cancer, the key to sales growth is to carve out a niche without competition, but ... For a while, Bavencio is was the only PD-1/PD-L1 to be approved for rare skin

  • CHMP recommends new Keytruda dosing schedule CHMP recommends new Keytruda dosing schedule

    The PD-1/PD-L1 class is a crowded one and Keytruda’s dominance hasn’t scared off new players from entering the field. ... Other PD-1/PD-L1 inhibitors approved for use are AstraZeneca’s Imfinzi, Pifzer and Merck’s Bavencio and Roche’s Tecentriq,

  • Merck puts prostate cancer firmly in Keytruda’s sights Merck puts prostate cancer firmly in Keytruda’s sights

    That combination has made prostate cancer an enticing target for drug developers and in particular those working on cancer immunotherapies, but both PD-1 and PD-L1 checkpoint inhibitors have largely ... The company thinks its phase 3 programme is the

  • Soon-Shiong presents first data on cancer memory vaccine at SITC Soon-Shiong presents first data on cancer memory vaccine at SITC

    Its ‘memory cancer vaccine’ consists of a cocktail of off-the-shelf NK cells delivered alongside low-dose chemotherapy, cytokines, yeast- and adenovirus-delivered tumour antigens and PD-1/PD-L1 ... checkpoint inhibitors – all designed to stimulate

More from news
Approximately 1 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing

  • The good, the bad and the ugly The good, the bad and the ugly

    Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response,” says Xuan.

  • European venture funding for the life science sector European venture funding for the life science sector

    is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    170. Checkpoint Therapeutics / TG. Licence and collaboration. Human anti-PD-L1 and anti-GITR antibody preclinical programmes for  haematological cancers. ... CAR-T and checkpoint inhibitors PD-1 and PD-L1. 110. Transtech / Calithera.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    PD-L1 and PD-1 CP inhibitors. Co-development and co-marketing alliance. 2, 850. ... FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics